Justin Taylor

Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor.

A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.

Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition.

Sex-Biased Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis.

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms.

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.

Advances in Acute Myeloid Leukemia: Recently Approved Therapies and Drugs in Development.

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.

Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.

Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of V600E Testing in Diagnosis and Treatment.

Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.

Splicing dysregulation in human hematologic malignancies: beyond splicing mutations.

Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.

Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.

An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS).

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14).

Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.

Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.

Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures.

Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms.

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.

Targeted Therapy Development in Acute Myeloid Leukemia.

Trying to outRun-DIC in KMT2Ar AML: It's tricky.

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1 International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).

Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era.